MegaPro Biomedical announced that its new MPB-1734 anti-cancer drug dosage form under the nanocell technology platform has been officially patented in the US.

Executive Vice President Yuan-Hong Hsu said that the nanomicrocell technology platform is used in the development of drug delivery systems (DDS), which utilises MegaPro's proprietary polymeric nanomicrocell technology. This is a significant improvement over the current commercially available dosage forms which require the use of emulsifiers of suspected allergenicity for injection and pre-treatment with steroids.

In addition, the nanosized nature of the drug changes the distribution of the drug in the body, significantly reducing the side effects of chemotherapy drugs. It also allows MPB-1734 to be used in patients who have developed resistance to chemotherapy because of its ability to bypass the P-Glycoprotein drug efflux pump.

In animal studies of head and neck cancer, MPB-1734 treatment was found to significantly increase the ability of immune cells to infiltrate the tumour (e.g. CD8+ T cells and other immune cell markers). MPB-1734 has the potential to be combined with immunotherapy in the future, not only for its own therapeutic effect, but also to change the tumour microenvironment from cold tumour, which is considered ineffective for immunotherapy, to hot tumour, achieving the best combined therapeutic effect.

MPB-1734 is currently being tested in clinical trials for patients with advanced solid tumours, and the company will be targeting ovarian cancer, which has a high recurrence rate, and head and neck cancer, which has a large number of patients, to provide a new drug for patients who are unable to continue treatment due to severe white blood cell depression. In the future, we will also expedite the process of obtaining drug certificates by applying to the US FDA for 505(b)(2) new dosage forms and orphan drugs, in the hope of benefiting patients and providing them with new treatment opportunities.